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Hypoxia in prostate cancer
Justyna Danielska1, Jolanta Łuniewska-Bury2, Łukasz Kuncman1, Jacek Fijuth1
Most human solid tumours contain areas which are less oxygenated than normal tissues. Hypoxia increases resistance 
to radiotherapy, surgery and chemotherapy, and directly alters the function of tumour cells, stimulating them to 
de-differentiate and to release angiogenic factors with a view to increasing the blood and oxygen supply. Tumour 
hypoxia promotes malignant progression and metastasis formation. HIF-1 is a heterodimeric transcription factor 
composed of regulated HIF-1a and constitutively expressed HIF-1b. Tumour-associated activation of HIF-1a seems 
to be primarily, however the result of adaptation to oxygen shortage. 
The presence of the HIF-1a subunit overexpression has been confirmed in many tumours, in prostate cancer, among 
others; the role it plays in its progression is yet to be explained. Numerous studies strongly emphasize the importance 
of evaluating the status of the HIF-1a transcription factor in predicting the clinical and biochemical recurrence of 
prostate cancer and its resistance to castration.
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Introduction
Prostate cancer is one of the most frequently diagnosed 
solid malignant tumours in the male population in the world. 
Prostate cancer is the second leading cause of neoplasms 
in men, accounting for over 13% of malignant tumours in 
Poland. Most tumours affect men over 65 years of age. Over 
the past three decades, the number of cases has increased 
five times [1]. Most patients have organ-confined or locally 
advanced tumours at the time of diagnosis [2].
The majority (90%) of prostate cancers are adenocar-
cinomas. Rare histopathological forms include sarcoma, 
squamous cell carcinoma, basal cell carcinoma, urothelial 
carcinoma, small cell carcinoma and others. The degree 
of histopathological variation in prostate cancer is evalu-
ated based on the Gleason classification, which provides 
important prognostic information. A higher Gleason score 
means a higher risk of progression, recurrence after radical 
treatment, growth of metastases and death.
Biochemical recurrence will occur in 15–50% of patients 
despite radical treatment; a part of patients will develop 
metastasis and die [2–3]. The rate of relapse depends on 
prognostic factors, such as the TNM stage, the degree of 
malignancy according to Gleason as well as the initial PSA 
(prostate-specific antigen) concentration. However, these 
factors only partially explain the variation in treatment effects.
Advances in medical genomics and molecular medi-
cine have revolutionized cancer research in recent years. 
Research into targeted therapies is underway, with the aim 
of ensuring long-term tumour control while causing fewer 
side effects than current standard treatments.
Strategic issues in prostate cancer treatment and diag-
nosis include not only identifying the group of patients with 
aggressive disease, but also developing personalized treat-
ment methods tailored to individual patients. More efficient 
prostate cancer markers than those used to date still need 
to be found. Priority should be given to finding markers for 
identifying high-risk patients in whom standard treatment 
modalities are unsatisfactory, and who would be eligible for 
clinical trials using more aggressive methods. Identifying the 
markers of prostate cancer would provide insight into the 
aetiology of the disease and into molecular mechanisms 
underlying its progression, thus setting the direction for the 
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search for new therapeutic targets. Progressive disorders 
of genes which regulate cell proliferation, differentiation 
and migration as well as signalling at the intracellular level 
affect the development of endothelial neoplasia in the first 
place and the occurrence of invasive prostate cancer in con-
sequence. Hypoxia, a hallmark of many human malignan-
cies, is considered to be a crucial modulator of the clinical 
features of cancer and the response to treatment, which is 
affected by genomic and molecular changes that induce 
local progression and the formation of metastases [4, 5]. 
Increasingly, the tumour microenvironment and hypoxia 
are investigated as potential prognostic factors in prostate 
cancer [6]. The expression of specific tumour hypoxia mark-
ers is an important predictor of therapeutic outcomes in 
many neoplasms, treated not only with ionizing radiation, 
but with surgery as well [7].
Hypoxia in a tumour
Hypoxia, as a pathophysiological consequence of the 
mismatch between oxygen supply and demand, is a feature 
of neoplasm resulting from high metabolic requirements of 
rapidly dividing neoplastic cells that depend on dynamic, 
unpredictable and ineffective neovascularization. Most solid 
tumours grow on their own blood supply, provided in a pro-
cess called angiogenesis. Increased oxygen demand leads 
to the growth of a chaotic network of blood vessels. In spite 
of intense neovascularization, tumours are characterised 
by low vascular density and a poorly developed network 
of arterioles, which impairs and reduces the efficiency of 
blood transport in the tumour.
Thomlinson and Gray were the first to report the pres-
ence of hypoxia in a malignant tumour in 1955 [8]. They 
examined histopathology slides from fresh tissue speci-
mens of human lung cancer. They observed vascularized 
areas of tumour which supplied oxygen and nutrients to 
tumour cells at a distance of 150–180 microns. Thomlinson 
and Gray discovered an area of living tumour cells capable 
of proliferation, surrounded by a rim of blood vessels, and 
a necrotic area in which anoxia developed along with the 
growth of the peripheral area of the tumour. Chronic hypoxia 
was defined by the presence of hypoxic, viable yet non-
oxygenated cells at the border between the oxygenated 
area and necrotic area. 
Today we know that cancer is a heterogeneous popula-
tion of cells with varying degrees of oxidation. Clinically sig-
nificant concentrations of hypoxia are detected in 50–60% of 
all malignancies [9]. Their oxidization is lower than in normal 
tissue, in which partial oxygen pressure ranges from 20 mm 
Hg in the liver and brain to 70 mm Hg in the kidneys [10, 11]. 
When the oxygen level in tissues falls below physiological 
norms, their capacity to perform normal cellular functions 
becomes impaired. Oxygen concentration below 10 mm Hg 
increases the expression of HIF-1 factor and activates many 
other molecular pathways which ensure the maintenance of 
basic cellular functions. This complex and dynamic response 
has massive implications such as increased angiogenesis, 
transition from aerobic to anaerobic metabolism, the inhibi-
tion of apoptosis and activation of growth factors as well as 
irreversible changes in cell genome [12–14]. 
The relative level of oxygen in the tumour during irra-
diation affects the effectiveness of radiotherapy. At partial 
oxygen pressure below 10 mmHg, neoplastic cells become 
hypoxic and 2–3 times more radioactive than well-oxidised 
cells. Radiation resistance of these cells is related to the 
lack of oxygen, which is responsible for the fixation of DNA 
damage caused by irradiation [15]. Radiation resistance of 
hypoxic cells in tumours is highest at p02 below 5 mmHg 
[16, 17]. 
Although it is acknowledged that hypoxic cell fractions 
are present in most neoplasms, their impact on progression, 
the formation of metastases and response to therapy varies, 
and it is unlikely to be equally relevant in all patients. 
HIF-1 is one of the most important proteins that allow 
cells to adapt to low levels of oxygen in the environment.
HIF-1 protein
HIF-1 protein (hypoxia-induced factor) is a heterodi-
meric transcription factor composed of two alpha and beta 
subunits [18, 19]. The following three genes have been iden-
tified in humans: HIF1A, EPAS1 and HIF3A, which encode 
HIF-1a, HIF-2a and HIF-3a, respectively [20, 21]. HIF-1a and 
HIF-2a have a similar structure, functions and regulatory 
pathways, whereas HIF-3a acts as an inhibitor of the tran-
scriptional response to hypoxia. Under aerobic conditions, 
the alpha subunit of HIF-1 protein is degraded in the cell via 
ubiquitization. The beta subunit is an oxygen-independent 
constitutive protein located in the cell nucleus [22]. The pro-
cess of alpha subunit degradation is initiated by posttransla-
tional hydroxylation of amino acids proline 402 and proline 
564 [23–25]. Because of hydroxylation, the alpha subunit 
of HIF protein is recognized by the von Hippel-Lindau pro-
tein (pVHL), a fragment of the ubiquitin ligase complex. 
A product of the VHL suppressor gene — the Hippel-Lindau 
protein (pVHL) — is attached to thus modified alpha subunit, 
followed by the ubiquitin molecule. The degradation of the 
alpha subunit takes place in the proteasome. 
Under hypoxic conditions no hydroxyl groups are at-
tached to the alpha subunit and no hydroxylation and in-
teraction with pVHL takes place. Subsequently, the HIF-1a 
protein preferentially associates with transcriptional coact-
ivators p300 and CBP. HIF-1 protein breakdown by ubiquiti-
zation becomes inhibited in consequence. At this point, the 
alpha subunit enters the cell nucleus and binds to the beta 
subunit, which stimulates gene expression in response to 
hypoxia. Hypoxia-regulated genes include those involved 
in angiogenesis (encoding VEGF — vascular endothelial 
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growth factor), glycosylation (encoding GLUT — glucose 
transporters), and pH control (encoding carbonate anhy-
drase IX) [22, 26]. 
Under hypoxic conditions, HIF-1 protein can induce the 
expression of several dozen genes that encode proteins 
responsible for energy metabolism, neovascularization, in-
tracellular pH and the migration of tumour cells. 
Even though the presence of HIF-1a transcription factor 
overexpression has been confirmed in many cancers includ-
ing breast, rectum, prostate and cervix cancers [27–32], its 
role in progression remains to be explained. High concentra-
tions of HIF-1a in renal and breast cancer cell lines increased 
tumour cell survival; in ovarian cancer, they were associated 
with enhanced apoptosis. The correlation between the in-
creased expression of HIF-1a and resistance to apoptosis as 
well as a worse prognosis is not the same in every neoplasm. 
In a non-small cell lung cancer study, Volm et al. have shown 
a relationship between the HIF-1a expression and tumour 
cell apoptosis and increased median survival [32]. Another 
study in a similar group of patients did not confirm these 
findings [33]. 
In many tumours HIF-1a overexpression is observed 
at an early stage of tumour development and it correlates 
with an increased density of vascularization in the lesion. 
Bos et al. have found that ductal in-situ carcinoma, which is 
an early pre-invasive stage of breast cancer, is characterized 
by an increased expression of HIF-1a protein, which is asso-
ciated with higher vascular tumour density [34]. The same 
phenomenon has been observed in ovarian cancer and in 
brain tumours, suggesting that HIF-1 activity contributes to 
amplified production of proangiogenic factors such as VEGF 
[35, 36]. The relationship between HIF-1a expression and 
tumour progression as well as the level of vascularization 
has also been proven in brain tumours [36]. 
Examining the expression of HIF-1a in nasopharyn-
geal carcinoma, Aebersold et al. have shown that patients 
with the HIF-1a expression in > 10% of neoplastic cells had 
a 3times lower chance of complete remission after radio-
therapy compared to those with increased expression of 
HIF-1a protein in < 10% of tumour cells [37]. 
Hypoxia in prostate cancer 
Four key methods are used in clinical practice to identify 
hypoxic cells in tumours: immunohistochemical evalua-
tion of protein expression — intracellular and extracellular 
hypoxia markers, microelectrodes, the imaging of hypoxic 
area and the imaging of haemoglobin oxidation. 
The existence of hypoxic areas in prostate cancer has 
been proved to date by many researchers [38, 40–42]. With 
immunohistochemistry tests, which use hypoxic cell mark-
ers and direct oxygen electrode measurements, clinically 
relevant levels of hypoxia are detected in 30–90% of pros-
tate cancer cases. Unfortunately, little is known about the 
influence of hypoxia on progression-free time and on long-
-term effects of radiotherapeutic and surgical treatment in 
prostate cancer. Vergis et al. examined tissue microarrays 
obtained from a group of 201 patients with locally advanced 
prostate cancer who underwent neoadjuvant hormone 
therapy and radiotherapy. Their research showed that in-
creased expression of HIF-1 protein and VEGF gene were in-
dependent factors associated with biochemical recurrence. 
Vergis et al. have demonstrated that increased expression 
of transcriptional factor HIF-1a is an independent predictor 
of biochemical progression in patients with prostate cancer 
treated with radiotherapy or prostatectomy [43]. Their find-
ings are consistent with the results presented by Movsas et 
al. [42] who examined a group of 57 patients with low- and 
intermediate-risk prostate cancer who received brachythera-
py. Movsas et al. have found a significant relationship between 
tumour oxidation and time to biochemical recurrence. This 
fact may indicate that hypoxia is a clinically important deter-
minant of disease progression. However, it should be borne in 
mind that increased expression of HIF-1 may also be induced 
by hypoxia-independent factors such as altered expression 
of oncogens and tumour suppressors, oxygen free radicals, 
androgens and other growth factors [44–46].
Researchers from the Princess Margaret Cancer Centre 
in Toronto conducted a prospective study in a group of 
247 prostate cancer patients in which Eppendorf micro-
electrodes were used for measuring oxygen pressure in 
prostate prior to radiotherapy. Median p02 was 6.8 mm 
Hg and the median percentage of hypoxia was less than 
10 mm Hg [47]. Their findings show that hypoxia is associ-
ated with early biochemical recurrence and local recurrence 
in prostate after radiotherapy or radiotherapy associated 
with hormone therapy. 
Researchers from the F. Łukaszczyk Centre of Oncology 
in Bydgoszcz analysed 43 paraffin blocks of prostate adeno-
carcinoma from patients after primary prostatectomy. They 
evaluated the severity of hypoxia in prostate tissues on the 
basis of HIF-1a protein expression analysis. The presence 
of hypoxia in primary tumour was observed in 90.7% of 
prostate cancer cases. The researchers have also reported 
a statistically significant correlation between the HIF-1a 
binding index and the tumours’ histological grade (degree 
of malignancy) on the Gleason scale [48]. In many other 
studies, no significant correlation was found between the 
HIF-1a expression and standard prognostic factors in pros-
tate cancer [27, 28, 49–51]. 
Zapatero et al. conducted a retrospective study eval-
uating the expression of HIF-1 alpha in a group of 86 men 
with intermediate and high-risk prostate cancer patients 
subjected to hypofractionated radiation therapy combined 
with hormonal therapy. The median follow-up time was 
10 years. Surprisingly, cytoplasmic overexpression of 
HIF-1a was associated with the improved overall survival [52].
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Prostate cancer is a hormone-dependent tumour whose 
systemic treatment consists chiefly in eliminating androgens 
from the body. The combination of radiotherapy with hor-
mone therapy in the treatment of locally advanced prostate 
cancer reduces clonogenic tumour cells and, thus, offers 
a greater chance of eliminating the remaining cells during 
radiotherapy. Moreover, the use of hormone therapy — by 
reducing the number of cells within the tumour — improves 
the oxygenation of the remaining cancer cells. Recent re-
search has shown that hormonal therapy enhances oxy-
genation in prostate cancer cells [53]. However, although 
hormonotherapy is highly efficient, some patients have pro-
gression after a period of time, which occurs because pros-
tate cancer cells are no longer dependent on endogenous 
androgens. In the 1990’s Visakorpi et al. demonstrated that 
under such circumstances, signal transduction pathways re-
lated to androgen receptors still functioned in prostate car-
cinoma cells and that the receptors themselves are activated 
regardless of the presence of endogenous androgens [54]. 
With testosterone at castration levels, castration resist-
ant prostate cancer (CRPC) is developed. CRPC is a deadly 
form of cancer, with a high metastatic potential. As many 
as 84% of patients have developed metastasis when resist-
ance to castration has been diagnosed. CRPC is linked with 
a significant deterioration of the quality of life [55]. Search-
ing for factors that will help identify the patients who will 
develop resistance to castration is of prime importance. 
Currently there are only a few biomarkers for identifying 
CRPC. Therapeutic possibilities are scarce for patients with 
this diagnosis [56, 57]. 
Ranasinghe et al. evaluated the role of HIF-1a in the 
formation of CRPC under in vitro conditions [58]. They exami-
ned three human prostate cancer cell lines (PC3, DU 145 
and LNCaP) and have shown that HIF-1a is an independent 
risk factor for CRPC development. HIF-1a expression was 
independent of the Gleason scale, tumour stage and treat-
ment that had been administered. Multivariate analysis has 
demonstrated that the risk of developing castration resis-
tant prostate cancer in patients with HIF-1a overexpression 
subjected to hormone therapy was 10 times higher. This 
observation clearly highlights the importance of assessing 
the status of transcriptional factor HIF-1a in predicting the 
development of prostate cancer castration resistance and in 
identifying patients eligible for novel second-line hormone 
therapy. 
Summary 
Hypoxia is a negative predictor of treatment outcome 
not only with via radiotherapy, but also via surgery and 
chemotherapy [59, 60]. It represents a strong rationale 
for research into the association of standard oncological 
treatment with hypoxia-guided factors. Finding a clinically 
relevant hypoxia test that will be inexpensive, non-invasive 
and reproducible remains to be the greatest challenge. 
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